APR 21, 2020 1:32 AM PDT

Classic Chemotherapeutic Repurposed for Treating Leukemia

WRITTEN BY: Nouran Amin

 

Researchers were seeking a promising new strategy to challenge drug resistance in leukemia. They found that targeted low doses of the widely-used chemotherapy drug doxorubicin is effective in overcoming resistance by leukemic cells.

"In low doses, doxorubicin actually stimulated the immune system, in contrast with the typical clinical doses, which were immunosuppressive, killing healthy immune cells indiscriminately," says John M. Perry, PhD, a researcher with the Children's Mercy Research Institute at Children's Mercy. He completed his postdoctoral work at Stowers and is first author of the report.

Doxorubicin is an anthracycline antibiotic that inhibits the interaction of two molecular pathways— Wnt/beta-catenin and PI3K/Akt--that promote tumor growth.

"Our idea was to find a drug with the goal of blocking the interaction between Wnt/beta-catenin and PI3K/Akt and reduce the toxicity," says Stowers Institute Investigator Linheng Li, PhD.

Findings were published in the journal Nature Cell Biology.

"We found that mice receiving patient sample transplants with therapy-resistant leukemia stem cells rapidly developed leukemia, but low-dose doxorubicin treatment improved survival by reducing leukemia stem cells," Perry says. "However, mice receiving patient sample transplants that did not contain therapy-resistant leukemia stem cells did not respond to low-dose doxorubicin treatment. These results showed that chemoresistant leukemia stem cells from patients could be functionally reduced with low-dose doxorubicin treatment, at least in an in vivo animal model assay."

Learn more about overcoming drug resistance in leukemia:

"The research holds promise as a more effective strategy to overcome cancer therapy resistance and immune escape that can be used in combination with other cancer therapies including chemotherapy, radiation, and immunotherapy for patients with leukemia and other types of cancer," Li says.

Source: Science Daily

 

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 09, 2020
Drug Discovery & Development
APR 09, 2020
Does Hydroxychloroquine Really Work Against COVID-19?
Although US President Donald Trump is a strong supporter of antimalarial drug Hydroxychloroquine as a treatment for COVI ...
APR 10, 2020
Drug Discovery & Development
APR 10, 2020
Cardiac Patch Repairs Heart Attack Damage in Pigs and Rats
Heart attacks significantly damage cardiac tissue. Recovery time frames from a heart attack thus depend on the extent to ...
APR 15, 2020
Chemistry & Physics
APR 15, 2020
Could this drug help people with SAD?
Have you ever been sad in the winter? If so, you’re not alone. Medaka fish feel it too. Seasonal affective disorde ...
APR 20, 2020
Cancer
APR 20, 2020
Expanding the Diagnostic Toolkit in Cancer Research with isomiRNAs
Esophageal cancers are one of the more common cancers around the world, with an unfortunately poor prognosis. The five-y ...
APR 25, 2020
Cancer
APR 25, 2020
Breaking the Blood-Brain Barrier in the Fight Against Brain Cancer
One of the more unique aspects of the human body is the blood-brain barrier (BBB) that protects the central nervous syst ...
APR 30, 2020
Drug Discovery & Development
APR 30, 2020
FDA to Approve Remdesivir to Fight COVID-19
A clinical trial investigating the ability of antiviral drug remdesivir to treat COVID-19 has found that it can signific ...
Loading Comments...